Compliance by Design and Compliance Master Plan - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Compliance by Design and Compliance Master Plan
The authors review a compliance-by-design approach to quality systems.


Pharmaceutical Technology
Volume 35, Issue 3, pp. 90-96

Analysis of each individual system. After all individual systems (e.g., stability system, training system) are identified, each is analyzed and evaluated. The following actions would be performed on the individual system:

  • Identify the complete business process for the system: These may be relatively complex with multiple individual functions with global components, or they may be less complex, such as the training system with a centralized function and direct involvement with all functional areas in a facility.
  • Identify system subsections: After the business process is identified, logical subsections can be determined that represent distinct groups of activities within the quality system. These may be individual departments within the organization. Identify objectives, critical compliance attributes, CPPs, variation, controls, and maintenance for all subsections.

Gap analysis for each individual system and subsystem. Identify any gaps in subsections and initiate corrective action. Procedures should be available for all significant activities in each subsystem. If needed, a commitment to develop new procedures should be made. Management, staff, and the quality assurance (QA) department should conduct this analysis with cross-functional input. Staff participation and cross-functional input is critical for the success of the analysis. Process experience, vendor audits, product data, deviations, corrective action and preventive action (CAPA), and other sources of information should be used to identify gaps or problem areas.

Risk analysis. Subsections are evaluated with regard to risk. If procedures are not appropriate for high-risk activities, they should be appropriately enhanced. Conversely, attention to lower-risk areas may be appropriately reduced. Risk to the patient, the process, and the organization (i.e., business risk) should be considered.

Continuous improvements. Continuous-improvement projects based on gap analysis, risk analysis, and system performance should be identified.

Performance measurement. Performance measurement parameters should be identified, monitored, and trended as appropriate. Corrective actions should be initiated as appropriate. Improvement projects should also be initiated as appropriate.

Documentation . All of these implementation strategies should be documented in the CMP.

A CbD example: materials system business process

This section provides a high-level description of the steps involved in the business process for the materials quality system in a pharmaceutical manufacturing facility.

  • Step 1: Identify approved vendors to source incoming materials (the vendor QA department audits potential suppliers and approves vendors)
  • Step 2: Incoming materials are received at manufacturing site.
  • Step 3: Incoming materials stored in pharmaceutical warehouse–quarantine status.
  • Step 4: Sample incoming materials based on defined sampling plan.
  • Step 5: Submit incoming materials for testing
  • Step 6: Receive and evaluate test results
  • Step 7: Transfer tested materials to appropriate status areas (at this stage, materials will be approved or rejected, with materials on test remaining in quarantine and rejected materials destroyed or returned to the supplier)
  • Step 8: Purified water, steam, nitrogen, and compressed air available in manufacturing area.
  • Step 9: Sample purified water, nitrogen, and compressed air based on defined sampling plan
  • Step 10: Receive and evaluate test results
  • Step 11: Dispense approved incoming materials to manufacturing areas
  • Step 12: Receive and store manufactured and finished products–quarantine status.
  • Step 13: Store tested materials in status areas (at this stage, materials on test are approved or rejected, with materials on test remaining in quarantine and rejected materials returned to manufacturing for rework or destroyed)
  • Step 14: Transfer approved materials to distribution center
  • Step 15: Ship approved materials from distribution center to customer.

Materials system subsections. After the business process is completed, appropriate subsections can be identified. For example, the materials system may include the following distinct subsystems:

  • Incoming materials—sourcing (Step 1)
  • Incoming materials—receipt and storage (Steps 2–7)
  • Purified water and compressed gases–material maintenance (Steps 8–10)
  • Dispensing—for future manufacturing (Step 11)
  • Finished products—storage (Steps 12–13)
  • Finished products—distribution (Steps 14–15).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here